Search

Zentalis Pharmaceuticals Inc

Lezárt

3.99 -2.92

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.94

Maximum

4.03

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+121.3% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

25M

356M

Előző nyitás

6.91

Előző zárás

3.99

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 5. 23:51 UTC

Core PPI Release on September 10 Expected to Show 0.3% Increase Amid Strong Employment Data and Speculation of Fed Rate Hikes Due to Inflation Concerns.

2026. szept. 5. 23:41 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% in August Amid Strong Job Growth and Heightened Interest Rate Hike Speculation

2026. szept. 5. 23:31 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid ECB Tightening and Investor Caution Ahead of September Release

2026. szept. 5. 23:01 UTC

Australia's Consumer Confidence Set for Release Amid Mixed Economic Signals and Global Uncertainties

2026. szept. 5. 22:51 UTC

Mexico's Inflation Rate Release on September 9, 2026, Sparks Market Concerns Amid Strong U.S. Jobs Data and Potential Interest Rate Adjustments.

2026. szept. 5. 22:51 UTC

Mexico's August 2026 Inflation Rate Release Expected to Influence Monetary Policy and Investor Confidence Amid Easing Trends.

2026. szept. 5. 22:51 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid positive market trends and strong U.S. job growth influencing economic outlook.

2026. szept. 5. 22:41 UTC

U.S. MBA 30-Year Mortgage Rate Set to Rise Amid Strong Job Growth and Inflation Concerns, Influencing Fed Interest Rate Expectations

2026. szept. 5. 22:31 UTC

Brazil's Central Bank readout on interest rates set for September 8, 2026, amid global economic influences and heightened speculation in financial markets.

2026. szept. 5. 22:21 UTC

Japan's Q2 2026 GDP Growth Forecast at 1.1% Amid Concerns Over Sharp Decline in Household Spending

2026. szept. 5. 22:21 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.4% Amid Mixed Economic Signals and Volatile Markets

2026. szept. 5. 22:11 UTC

Turkey's TCMB Expected to Maintain 37% Interest Rate Amid Inflation Concerns and Global Market Influences Ahead of September Decision.

2026. szept. 5. 22:11 UTC

UK Housing Market Sentiment Remains Negative as RICS House Price Balance Forecasts Slight Improvement Amid Broader Economic Concerns

2026. szept. 5. 21:51 UTC

South Korea's Unemployment Rate Release on September 8, 2026, Expected Amid Global Job Growth Optimism Following Strong U.S. Data

2026. szept. 5. 21:31 UTC

Cautious Market Sentiment Ahead of BRC Retail Sales Monitor YoY Release, Forecasting 1.2% Growth Amid Mixed Economic Signals

2026. szept. 5. 21:21 UTC

Spain's Consumer Confidence Index set for release on September 8, with analysts hopeful for improvement amid geopolitical tensions and inflation concerns.

2026. szept. 5. 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Trends.

2026. szept. 5. 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Recovery Signals.

2026. szept. 5. 20:41 UTC

Japan's Current Account Surplus Forecasted at JPY 2,870 Billion Amid Cautious Sentiment from Declining Household Spending

2026. szept. 5. 19:21 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Anticipated Amid Geopolitical Tensions and Recent Inventory Volatility.

2026. szept. 5. 19:11 UTC

Italy's Industrial Production MoM data for July 2026 set to release on September 10, with a forecasted increase of only 0.3% amid declining trends and mixed signals from Europe.

2026. szept. 5. 19:01 UTC

Correlated Moves

Cardano is rising during Saturday's session, supported by Ethereum's performance. The asset is trading above its 20-day moving average, reflecting strong momentum.

2026. szept. 5. 18:31 UTC

Swiss Consumer Confidence Index Expected to Remain Low at -32.0 Amidst Cautious Market Sentiment and Global Economic Concerns

2026. szept. 5. 18:11 UTC

EUR/SEK is trading roughly flat in after-market hours, showing little change since Friday's close and remaining near the upper end of its one-month range.

2026. szept. 5. 18:11 UTC

EUR/CAD is trading roughly flat in after-market hours, showing little change from Friday's close and remaining near the lower end of its one-month range.

2026. szept. 5. 18:11 UTC

Turkey's Industrial Production YoY data release on September 10, 2026, may reflect cautious optimism amid recent fluctuations and mixed market sentiment.

2026. szept. 5. 17:41 UTC

U.S. Monthly Budget Statement on September 11, 2026, expected to reveal rising deficits amid cautious fiscal sentiment and potential Fed interest rate decisions.

2026. szept. 5. 17:41 UTC

France's Industrial Production Expected to Rise 0.3% Amid Cautious Economic Sentiment and Construction Sector Decline

2026. szept. 5. 17:31 UTC

UK's Non-EU Goods Trade Balance Report Set for Release on September 11, 2026 Amidst Stable Market Sentiment.

2026. szept. 5. 17:31 UTC

UK Monthly GDP Expected to Remain Flat at 0.0% for July Amid Cautious Investor Sentiment and Mixed Economic Signals

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

121.3% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  121.3%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat